BioCentury | Dec 1, 2016
Clinical News

Atacicept: Ph IIb ADDRESS II data

...SLE patients receiving standard of care (SOC) showed that once-weekly 75 and 150 mg subcutaneous atacicept...
...atacicept also significantly reduced the incidence of BILAG A flare vs. placebo (p=0.019) and high-dose atacicept...
...Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. Merck KGaA (Xetra:MRK), Darmstadt, Germany Product: Atacicept (formerly TACI-Ig...
BioCentury | Sep 18, 2014
Translation in Brief

Translational tidbits

...marketed for LN. Serono has one disclosed therapeutic in Phase II testing to treat SLE, atacicept...
BioCentury | Feb 4, 2013
Company News

Merck KGaA, Feinstein Institute deal

...antibodies resulting from the deal. The partners did not disclose details. Merck Serono's pipeline includes atacicept...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

...S.A. , a unit of Merck KGaA (Xetra:MRK). Led early and late development programs, including atacicept...
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...outside Japan to Kuvan from Daiichi Sankyo Co. Ltd. The two remaining Serono compounds are atacicept...
...announced further development plans for the mAb, which targets epithelial cell adhesion molecule (EpCAM) antigen. Atacicept...
...Kuvan sapropterin dihydrochloride Phenylketonuria (PKU) Ph III Mkt in EU BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Atacicept (TACI-Ig...
BioCentury | Nov 22, 2010
Regulation

Mild Was Enough

...Humanized mAb targeting CD22 Ph III (start 4Q10) Merck KGaA (Xetra:MRK)/Bristol-Myers Squibb Co. (NYSE:BMY) Atacicept (TACI-Ig...
BioCentury | Oct 4, 2010
Strategy

Times changed

...a 2001 deal with Merck Serono S.A. , which had been co-funding development of ZymoGenetics' atacicept...
BioCentury | Oct 12, 2009
Analyst Picks & Changes

Analysts Picks & Changes

...Neutral 1% $5.96 Elliot raised his target to $6.50 from $5.50 on the expectation that atacicept...
...even though partner Merck KGaA (Xetra:MRK) discontinued a study of atacicept to treat lupus nephritis. Atacicept...
BioCentury | Oct 5, 2009
Finance

3Q Approvals/3Q Setbacks

...trial showed the compound missed all secondary efficacy endpoints ZymoGenetics Inc. (NASDAQ:ZGEN)/ Merck KGaA (Xetra:MRK) Atacicept...
...a pair of Phase II trials to treat RA; discontinues ongoing Phase II studies for atacicept...
BioCentury | Oct 5, 2009
Finance

Ebb & Flow

...disclosing in an SEC filing on Monday that partner Merck KGaA (Xetra:MRK) discontinued studies of atacicept...
Items per page:
1 - 10 of 70